These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 6439262

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Platelet prostanoids in interaction of platelets with collagen substrates. II. Effects of exogenous arachidonic acid, stable PG endoperoxides analogue, and aspirin.
    Mazurov AV, Leytin VL, Repin VS, Taube C, Förster W.
    Biomed Biochim Acta; 1984; 43(8-9):S373-6. PubMed ID: 6440553
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
    Mevkh AT, Basevich VV, Varfolomeev SD.
    Biokhimiia; 1984 Dec; 49(12):2035-40. PubMed ID: 6441604
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
    Parise LV, Venton DL, Le Breton GC.
    J Pharmacol Exp Ther; 1982 Jul; 222(1):276-81. PubMed ID: 7086705
    [Abstract] [Full Text] [Related]

  • 10. Effects of the prostaglandin H2/thromboxane A2 antagonist BM 13.177 on human platelets.
    Patscheke H, Stegmeier K.
    Adv Prostaglandin Thromboxane Leukot Res; 1985 Jul; 13():371-3. PubMed ID: 3159225
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Thromboxane synthase inhibitors suppress more effectively the aggregation of thromboxane receptor-desensitized than that of normal platelets: role of adenylylcyclase up-regulation.
    Vezza R, Nenci GG, Gresele P.
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1497-505. PubMed ID: 8531121
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
    Block HU, Förster W, Heinroth I.
    Arzneimittelforschung; 1982 Dec; 32(3):189-94. PubMed ID: 6896278
    [Abstract] [Full Text] [Related]

  • 15. Interference of the thromboxane antagonist SK&F 88046 with platelet activation and subsequent desensitization by arachidonic acid and the thromboxane mimetics U46619 and EP171.
    Vargaftig B, Joseph D, Hatmi M.
    Thromb Res; 1987 May 15; 46(4):509-17. PubMed ID: 3039684
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism.
    Macconi D, Morzenti G, Livio M, Morelli C, Cassina G, Remuzzi G.
    Lab Invest; 1985 Feb 15; 52(2):159-68. PubMed ID: 3155816
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.